Pressure BioSciences Inc (OTCMKTS:PBIO) announced Thursday that its patented pressure cycling technology (PCT) was prominently featured recently at a major conference in Australia.
In a statement, the Massachusetts-based company said PCT was featured in 10 separate presentations from scientists affiliated with 17 leading research institutions worldwide at the International Human Proteome Organization World Congress held September 15-18 in Adelaide, Australia.
The HUPO plays a pivotal role in defining and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques, and training to better understand the full complement and roles of proteins in human health and disease.
The multiple presentations included the development of new methods and applications using Pressure BioScience’s PCT platform to advance knowledge and understanding in areas such as cancer research, with particular focus on cancer biomarker discovery.
"We are delighted to note that the number of PCT-related presentations at important international meetings is now exploding, in response to our years of investment in building collaborations and supporting research and the publication of now over 150 peer-reviewed scientific articles,” said Roxana McCloskey, the company’s global director of sales and marketing.
The company noted that the PCT-related presentations were primarily in the key areas of new and approved methods and protocols and in new applications for the discovery and identification of cancer markers.
Several presentations also illustrated the flexibility of PCT to extract proteins and nucleic acids from different types of tissue biopsies used in the characterization of specific cancers.
Data presented from a study conducted by 12 scientists from four leading academic and research institutions in China demonstrated the effectiveness and practicality of PCT in a study of colorectal cancer.
Another study showed PCT to be an effective component of the workflow to help highlight details of gastric cancer.
And another cancer-related study showed that the combination of PCT and mass spectrometry could result in a superior method for “ruling-in and ruling-out” cancer in thyroid nodules compared to current diagnostic tests.
“We are excited that international teams of scientists from more than seventeen institutions on four continents contributed to presentations showing the power and versatility of PCT for cancer research, biomarker discovery, proteomics, and molecular biology," said Dr Nate Lawrence, senior consultant to Pressure BioSciences.
“It has been projected that these combined markets are expected to be in excess of $200 billion by 2025.”
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham